Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02485652 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Phase 2 study, sponsored by Hanmi Pharmaceutical Company Limited.
- Terminated
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT02485652 is a Phase 2 study that was terminated before completion, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 162 participants.
The verdict
NCT02485652, a Phase 2 study, was terminated before completion, sponsored by Hanmi Pharmaceutical Company Limited.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
Interventions
- DRUG HM61713
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2015-08-31 |
| Est. Completion | 2020-12-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02485652
The ClinicalTrials.gov registry entry for NCT02485652 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hanmi Pharmaceutical Company Limited, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HM61713 is the first listed.
NCT02485652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02485652 about?
NCT02485652 is a clinical study titled "Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung". The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
What is the current status of trial NCT02485652?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2015-08-31. Estimated completion is 2020-12-08.
What interventions are being tested in trial NCT02485652?
The interventions under investigation include: HM61713 (DRUG).
Who is sponsoring clinical trial NCT02485652?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.